Short answer
ADMA BIOLOGICS, INC. (ADMA) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $134M (up 12.0% year over year) with net income of $36M.
Q3 2025 key financials · XBRL
- Revenue
- $134M
- +12.0% YoY · +10.0% QoQ
- Net income
- $36M
- +1.4% YoY · +6.5% QoQ
- Operating margin
- 38.0%
- Gross margin
- 56.3%
- EPS (diluted)
- $0.15
- +7.1% YoY · +7.1% QoQ
Source: XBRL data from the ADMA BIOLOGICS, INC. (ADMA) Q3 2025 10-Q on SEC EDGAR. USD.
ADMA BIOLOGICS, INC. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: FDA approval of yield enhancement production process in April 2025 may impact revenue forecasts and operational scaling
- Most updated risk: Net income of $197.7M in 2024 vs prior losses, with increased operating expenses due to commercialization and R&D expansion
- Regulatory risk: Periodic FDA inspections could lead to enforcement actions, including warning letters and shutdowns affecting production continuity
- Operational risk: Reliance on limited third-party contractors for fill/finish and plasma supply poses supply chain disruption and quality control risks
- Financial risk: Accumulated deficit $308.6M through 2024; need for continued positive cash flow to avoid equity or debt financing or collaborations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ADMA BIOLOGICS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.